ESMO Breast 2024 | Axillary management for breast cancer in the post-neoadjuvant setting

Elisabetta Munzone, MD, Istituto Europeo di Oncologia, Milan, Italy, discusses management strategies for the axilla in the post-neoadjuvant setting. Dr Munzone goes through the role of endocrine therapy, highlighting findings from the SOFT (NCT00066690) and TEXT (NCT00066703) trials, as well as the role of CDK4/6 inhibitors such as abemaciclib and ribociclib in the monarchE (NCT03155997) and NATALEE (NCT03701334) trials respectively. This interview took place at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.